Characteristics | |
---|---|
Sex | |
Male | 85 (77%) |
Female | 25 (23%) |
Age (range) (mean) (median) (yr) | 30–87, 59, 58 |
Primary tumor location | |
Oropharynx | 51 (46%) |
Oral cavity | 19 (17%) |
Larynx | 19 (17%) |
Hypopharynx | 6 (6%) |
Nasopharynx | 6 (6%) |
Unknown primary | 5 (5%) |
Paranasal sinuses/nasal cavity | 4 (3%) |
HPV status (oropharynx) (n = 51) | |
Positive | 35 (69%) |
Negative | 8 (15.5%) |
Unknown | 8 (15.5%) |
Tumor stage (AJCC Cancer Staging Manual, 7th ed) | |
T-stage | |
T0 | 5 (5%) |
T1 | 22 (20%) |
T2 | 30 (27%) |
T3 | 25 (23%) |
T4 | 28 (25%) |
N-stage | |
N0 | 28 (25%) |
N1 | 17 (15%) |
N2 | 61 (57%) |
N3 | 4 (3%) |
M-stage | |
M0 | 107 (97%) |
M1 | 3 (3%) |
MX | 0 (0%) |
TNM stage | |
I | 1 (1%) |
II | 9 (8%) |
III | 22 (20%) |
IV | 78 (71%) |
Interval between the first posttreatment PET/CT and completion of chemoradiation (range) (mean) (median) (wk) | 3–46, 11, 9 |
Duration of follow-up (range) (mean) (median) (yr) | 1.3–9.7, 4.9, 4.4 |
Total patients with residual or recurrent disease within 2 yr after scompletion of primary chemoradiation therapya | 17/110 (15%) |
Note:—HPV indicates human papillomavirus; TNM, Tumor, Node, Metastasis.
↵a NPV = 85% (95% CI, 77%–90%).